You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

MASS. MOVERS

Ariad rises again, despite setback on drug

THE BOSTON GLOBE/FILE 2011

Ariad focuses on developing anticancer medicines.

Shares of Ariad Pharmaceuticals Inc. climbed again Thursday, despite this week’s vote against the Cambridge company’s first cancer-fighting drug by a Food and Drug Administration panel. It recommended against FDA approval for Ridaforolimus, a treatment for metastatic soft-tissue sarcoma and bone sarcoma. But investors are apparently more excited about a third-quarter application for Ponatinib, for chronic myeloid leukemia. Analysts said Ponatinib, which could generate annual sales of $1 billion, drives the stock than Ridaforolimus.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.